Understanding and harnessing the graft-versus-leukaemia effect
- PMID: 18564358
- DOI: 10.1111/j.1365-2141.2008.07260.x
Understanding and harnessing the graft-versus-leukaemia effect
Abstract
The graft-versus-leukaemia (GVL) effect is a central component of the stem cell allograft's ability to cure haematological malignancies. The GVL effect is mediated by donor-derived natural killer cells and T lymphocytes, which have distinct mechanisms of recognizing and targeting the recipient's malignant cells. After transplantation the cytokine milieu is favourable to the early establishment of a GVL effect, but the need to prevent graft-versus-host disease limits the full potential of this process. Clinical studies have identified some critical components of the transplant preparation, donor selection, stem cell source (peripheral blood versus bone marrow) and post-transplant management that can be manipulated to optimize the GVL effect. However, further developments focusing on the selective depletion of unwanted alloreactivity with preservation of GVL effects, and the use of vaccines or the adoptive transfer of leukaemia-specific lymphocytes, will be required to enhance the GVL effect to reliably eradicate more resistant leukaemias.
Similar articles
-
Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.Front Immunol. 2018 Dec 21;9:3041. doi: 10.3389/fimmu.2018.03041. eCollection 2018. Front Immunol. 2018. PMID: 30619371 Free PMC article. Review.
-
The allogeneic graft-versus-cancer effect.Br J Haematol. 2009 Dec;147(5):614-33. doi: 10.1111/j.1365-2141.2009.07886.x. Epub 2009 Sep 4. Br J Haematol. 2009. PMID: 19735262 Review.
-
Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.Nat Clin Pract Oncol. 2007 Jul;4(7):404-14. doi: 10.1038/ncponc0848. Nat Clin Pract Oncol. 2007. PMID: 17597705 Review.
-
Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.Transfusion. 2010 Feb;50(2):418-28. doi: 10.1111/j.1537-2995.2009.02440.x. Epub 2009 Oct 15. Transfusion. 2010. PMID: 19843288
-
Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.Br J Haematol. 2010 Jun;149(6):879-89. doi: 10.1111/j.1365-2141.2010.08164.x. Epub 2010 Mar 21. Br J Haematol. 2010. PMID: 20346011
Cited by
-
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.Cancer Immunol Immunother. 2022 Dec;71(12):2913-2928. doi: 10.1007/s00262-022-03202-8. Epub 2022 Apr 27. Cancer Immunol Immunother. 2022. PMID: 35476127 Free PMC article. Clinical Trial.
-
Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Mol Ther. 2016 Sep;24(9):1655-64. doi: 10.1038/mt.2016.147. Epub 2016 Jul 6. Mol Ther. 2016. PMID: 27401140 Free PMC article.
-
Transplantation immunology: solid organ and bone marrow.J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S324-35. doi: 10.1016/j.jaci.2009.11.014. J Allergy Clin Immunol. 2010. PMID: 20176267 Free PMC article. Review.
-
Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2019 Feb;25(2):216-222. doi: 10.1016/j.bbmt.2018.09.037. Epub 2018 Oct 4. Biol Blood Marrow Transplant. 2019. PMID: 30292745 Free PMC article. Clinical Trial.
-
Histamine dihydrochloride: in the management of acute myeloid leukaemia.Drugs. 2011 Jan 1;71(1):109-22. doi: 10.2165/11206410-000000000-00000. Drugs. 2011. PMID: 21175244 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
